| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.26 | 5e-12 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | 0.24 | 8e-11 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.22 | 8e-09 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-05 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-05 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.12 | 5e-05 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0002 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0003 |